Scribe Therapeutics is a speculative biotech with heavy insider buying and large analyst-implied upside, but it sits below the market-cap floor and its revenue is shrinking.
Thesis pillars
- Heavy Insider Buying Conviction↓Deteriorating
- Analyst Target Implies Large Upside↓Deteriorating
- Market Cap Below Universe Floor↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 18, 2026
Scribe Therapeutics Inc. (SCTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $17.54, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $57.00 vs price $17.54 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $332M below $400M minimum.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company... Read more
Hold if already holding. Not a fresh buy at $17.54, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $57.00 vs price $17.54 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $332M below $400M minimum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Market cap $332M below $400M minimum. Not in investable universe. Score 4.4/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Scribe Therapeutics Inc.
Latest news
- NEWS Biocom California Recognizes Scribe Therapeutics' Ioana Aanei in 11th Annual Life Science Catalyst Awards — fiscal.ai Oct 26, 2026
- NEWS Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday — benzinga Oct 14, 2026
- NEWS Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up — benzinga Oct 6, 2026
- NEWS 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga Sep 30, 2026
- NEWS Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets — benzinga Sep 22, 2026 neutral
Generated 2026-10-29T11:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -97.0%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.54, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $57.00 vs price $17.54 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $332M below $400M minimum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Market cap $332M below $400M minimum. Not in investable universe. Resistance target $21.63 (+23.3%), stop $16.31 (−7.5%), A.R:R 0.0:1. Score 4.4/10, moderate confidence.
Resistance target: $21.63 (+23.3% upside). Resistance target $21.63 (+23.3%), stop $16.31 (−7.5%), A.R:R 0.0:1. Stop-loss: $16.31.
DATA_ISSUE: analyst_target_implausible (raw $57.00 vs price $17.54 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $332M below $400M minimum.
Scribe Therapeutics Inc. trades at a P/E of N/A (forward -4.8). TrendMatrix value score: 3.5/10. Verdict: Hold.
10 analysts cover SCTX with a consensus score of 4.3/5. Average price target: $57.
What does Scribe Therapeutics Inc. do?Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic...
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.